# 1st Gen Model Eli Lilly and Company Pharmaceutical preparations
at 21-jul-2017
LLY
Model's trade recommendations -0.15% Return for period
1.50% Annual return
$92.94B Market Cap
β 0.35
LLY
Model (following trade recommendations)LLY
Underlying stockS&P 500
Index- 2.08 (2.47%) Div (Yield)
- BUY Analysts consensus recommendation
Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Eli Lilly and Company (LLY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for LLY model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1101M |
| P/E | 22.95 |
| Shares Outstanding | 1103M |
| % Held by Insiders | 0.20% |
| % Held by Institutions | 75.47% |
| EPS (last reported FY) | $3.52 |
| EPS (last reported Q) | $0.98 |
| EPS, estimated (last reported Q) | $0.96 |
| Total revenues | $21 B |
| Net income | $3 B |